SGX301

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company with a bifurcated strategy targeting high-value niches. Its mission is to develop and commercialize novel therapies for rare diseases with significant unmet medical needs, particularly in cutaneous T-cell lymphoma and oral mucositis, while leveraging U.S. government funding to advance a portfolio of biodefense countermeasures. The company's key achievements include positive Phase 3 results for its lead asset, SGX301, and the receipt of multiple government grants and contracts supporting its public health pipeline. Soligenix's strategy is to de-risk development through non-dilutive government funding, advance its late-stage clinical assets toward regulatory submissions, and seek strategic partnerships for commercialization.

Therapeutic Areas

Other Cutaneous T-Cell Lymphoma (CTCL) Drugs